

Jacques De Keyser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4021202/publications.pdf>

Version: 2024-02-01

350
papers

18,758
citations

13865

67
h-index

17592

121
g-index

353
all docs

353
docs citations

353
times ranked

18942
citing authors

#	ARTICLE	IF	CITATIONS
1	Opposite effects of one session of 1ÂHz rTMS on functional connectivity between pre-supplementary motor area and putamen depending on the dyskinesia state in Parkinson's disease. <i>Clinical Neurophysiology</i> , 2021, 132, 851-856.	1.5	9
2	Usefulness of the Neutrophil-to-Lymphocyte Ratio as a Predictor of Pneumonia and Urinary Tract Infection Within the First Week After Acute Ischemic Stroke. <i>Frontiers in Neurology</i> , 2021, 12, 671739.	2.4	8
3	Modulation of Cytokine-Induced Astrocytic Endothelin-1 Production as a Possible New Approach to the Treatment of Multiple Sclerosis. <i>Frontiers in Pharmacology</i> , 2020, 10, 1491.	3.5	10
4	Correlations of health status indicators with perceived neuropsychological impairment and cognitive processing speed in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 101904.	2.0	11
5	Relation between Heart Rate Variability and Disease Course in Multiple Sclerosis. <i>Journal of Clinical Medicine</i> , 2020, 9, 3.	2.4	28
6	The Role of Cerebral Hypoperfusion in Multiple Sclerosis (ROCHIMS) Trial in Multiple Sclerosis: Insights From Negative Results. <i>Frontiers in Neurology</i> , 2020, 11, 674.	2.4	4
7	Post-stroke infections associated with spleen volume reduction: A pilot study. <i>PLoS ONE</i> , 2020, 15, e0232497.	2.5	14
8	Gut microbiome variation is associated to Multiple Sclerosis phenotypic subtypes. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 406-419.	3.7	59
9	Response to Grech et al.: FLOUX-PMS study sample considerations. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1820-1821.	3.0	4
10	Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1728-1735.	3.0	25
11	The influence of one session of low frequency rTMS on pre-supplementary motor area metabolites in late stage Parkinson's disease. <i>Clinical Neurophysiology</i> , 2019, 130, 1292-1298.	1.5	7
12	Perceived neuropsychological impairment inversely related to self-reported health and employment in multiple sclerosis. <i>European Journal of Neurology</i> , 2019, 26, 1447-1454.	3.3	15
13	Role of cerebral hypoperfusion in multiple sclerosis (ROCHIMS): study protocol for a proof-of-concept randomized controlled trial with bosentan. <i>Trials</i> , 2019, 20, 164.	1.6	7
14	Single MRIâ€Based Volumetric Assessment in Clinical Practice Is Associated With MSâ€Related Disability. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 49, 1312-1321.	3.4	13
15	Plasma citrulline levels are increased in patients with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2018, 387, 174-178.	0.6	9
16	Meningoencephaloradiculitis following infection with tick borne encephalitis virus: case report and review of the literature. <i>Acta Neurologica Belgica</i> , 2018, 118, 93-96.	1.1	6
17	European Academy of Neurology and European Stroke Organization consensus statement and practical guidance for pre-hospital management of stroke. <i>European Journal of Neurology</i> , 2018, 25, 425-433.	3.3	83
18	Post-stroke treatment with 17Î²-estradiol exerts neuroprotective effects in both normotensive and hypertensive rats. <i>Neuroscience</i> , 2017, 348, 335-345.	2.3	4

#	ARTICLE	IF	CITATIONS
19	Definition, prevalence and predictive factors of benign multiple sclerosis. <i>ENeurologicalSci</i> , 2017, 7, 37-43.	1.3	36
20	Rapidly Progressive Cerebellar Hemiataxia with High Levels of <sc>GAD</sc>65 Reactive Antibodies. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 632-634.	1.5	4
21	A transient ischemic attack mimic. <i>Acta Neurologica Belgica</i> , 2017, 117, 919-920.	1.1	2
22	Role of infarct location and pre-existing depression on cardiac baroreceptor sensitivity in subacute ischemic stroke. <i>Acta Neurologica Belgica</i> , 2017, 117, 655-659.	1.1	2
23	Absence of system xc ⁻ on immune cells invading the central nervous system alleviates experimental autoimmune encephalitis. <i>Journal of Neuroinflammation</i> , 2017, 14, 9.	7.2	20
24	Astrocytic α_2 -Adrenergic Receptors and Multiple Sclerosis. , 2017, , 289-299.		0
25	Pregnancy Considerations and Pregnancy Outcomes in Women with MS. , 2017, , 19-34.		0
26	Two Time Point MS Lesion Segmentation in Brain MRI: An Expectation-Maximization Framework. <i>Frontiers in Neuroscience</i> , 2016, 10, 576.	2.8	32
27	Admission hyperglycemia and outcome after intravenous thrombolysis: is there a difference among the stroke-subtypes?. <i>BMC Neurology</i> , 2016, 16, 104.	1.8	14
28	Astrocytic α_2 Adrenergic Receptor Gene Deletion Affects Memory in Aged Mice. <i>PLoS ONE</i> , 2016, 11, e0164721.	2.5	28
29	Central <sc>IGF</sc> Receptors in the Brain are Instrumental to Neuroprotection by Systemically Injected <sc>IGF</sc> in a Rat Model for Ischemic Stroke. <i>CNS Neuroscience and Therapeutics</i> , 2016, 22, 611-616.	3.9	24
30	Self-reported levels of education and disability progression in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2016, 134, 414-419.	2.1	22
31	The pathophysiological role of astrocytic endothelin-1. <i>Progress in Neurobiology</i> , 2016, 144, 88-102.	5.7	59
32	Reliable measurements of brain atrophy in individual patients with multiple sclerosis. <i>Brain and Behavior</i> , 2016, 6, e00518.	2.2	58
33	SCN4A variants and Brugada syndrome: phenotypic and genotypic overlap between cardiac and skeletal muscle sodium channelopathies. <i>European Journal of Human Genetics</i> , 2016, 24, 400-407.	2.8	33
34	Bilateral low frequency rTMS of the primary motor cortex may not be a suitable treatment for levodopa-induced dyskinesias in late stage Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 22, 62-67.	2.2	30
35	Estimated GFR and the Effect of Intensive Blood Pressure Lowering After Acute Intracerebral Hemorrhage. <i>American Journal of Kidney Diseases</i> , 2016, 68, 94-102.	1.9	31
36	Development and Pilot Testing of 24/7 In-Ambulance Telemedicine for Acute Stroke: Prehospital Stroke Study at the Universitair Ziekenhuis Brussel-Project. <i>Cerebrovascular Diseases</i> , 2016, 42, 15-22.	1.7	32

#	ARTICLE	IF	CITATIONS
37	The Effect of Age and Sex on Clinical Outcome after Intravenous Recombinant Tissue Plasminogen Activator Treatment in Patients with Acute Ischemic Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2016, 25, 312-316.	1.6	24
38	A 10-year follow-up of the European multicenter trial of interferon β -1b in secondary-progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 533-543.	3.0	24
39	Feasibility, Reliability and Predictive Value Of In-Ambulance Heart Rate Variability Registration. <i>PLoS ONE</i> , 2016, 11, e0154834.	2.5	8
40	ID: 190. <i>Cytokine</i> , 2015, 76, 98.	3.2	0
41	Heart Rate Variability and Baroreceptor Sensitivity in Acute Stroke: A Systematic Review. <i>International Journal of Stroke</i> , 2015, 10, 796-800.	5.9	82
42	The European Stroke Organisation Guidelines: a standard operating procedure. <i>International Journal of Stroke</i> , 2015, 10, 128-135.	5.9	41
43	PreSSUB II: The prehospital stroke study at the Universitair Ziekenhuis Brussel II. <i>Journal of Translational Internal Medicine</i> , 2015, 3, 57-63.	2.5	3
44	High natural killer cell number might identify stroke patients at risk of developing infections. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e71.	6.0	19
45	Cerebral Hypoperfusion: A New Pathophysiologic Concept in Multiple Sclerosis?. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 1406-1410.	4.3	92
46	Autonomic dysfunction in acute ischemic stroke: An underexplored therapeutic area?. <i>Journal of the Neurological Sciences</i> , 2015, 348, 24-34.	0.6	94
47	Reduced information processing speed as primum movens for cognitive decline in MS. <i>Multiple Sclerosis Journal</i> , 2015, 21, 83-91.	3.0	63
48	Do Advanced Statistical Techniques Really Help in the Diagnosis of the Metabolic Syndrome in Patients Treated With Second-Generation Antipsychotics?. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e1292-e1299.	2.2	5
49	Feasibility of Ambulance-Based Telemedicine (FACT) Study: Safety, Feasibility and Reliability of Third Generation In-Ambulance Telemedicine. <i>PLoS ONE</i> , 2014, 9, e110043.	2.5	58
50	Multiparity in women with multiple sclerosis causes less long-term disability: Yes. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1432-1434.	3.0	4
51	Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in a Stroke Patient Treated with Apixaban. <i>International Journal of Stroke</i> , 2014, 9, E31-E31.	5.9	9
52	Single-subject classification of schizophrenia patients based on a combination of oddball and mismatch evoked potential paradigms. <i>Journal of the Neurological Sciences</i> , 2014, 347, 262-267.	0.6	25
53	Prehospital Stroke Care: Limitations of Current Interventions and Focus on New Developments. <i>Cerebrovascular Diseases</i> , 2014, 38, 1-9.	1.7	42
54	Relative contribution of cognitive and physical disability components to quality of life in MS. <i>Journal of the Neurological Sciences</i> , 2014, 336, 116-121.	0.6	7

#	ARTICLE	IF	CITATIONS
55	Fluoxetine in Progressive Multiple Sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 37.	1.6	16
56	Intracranial artery dissection. <i>European Journal of Neurology</i> , 2014, 21, 820-826.	3.3	63
57	SVM aided detection of cognitive impairment in MS. , 2014, , .		3
58	Validation assessment of risk tools to predict outcome after thrombolytic therapy for acute ischemic stroke. <i>Clinical Neurology and Neurosurgery</i> , 2014, 125, 189-193.	1.4	14
59	In search of biomarkers for schizophrenia using electroencephalography. , 2014, , .		0
60	Î2-Adrenergic receptors protect axons during energetic stress but do not influence basal glyo-axonal lactate shuttling in mouse white matter. <i>Neuroscience</i> , 2014, 277, 367-374.	2.3	8
61	Î2-adrenergic agonists modulate TNF-Î± induced astrocytic inflammatory gene expression and brain inflammatory cell populations. <i>Journal of Neuroinflammation</i> , 2014, 11, 21.	7.2	36
62	Graph theoretical analysis indicates cognitive impairment in MS stems from neural disconnection. <i>NeuroImage: Clinical</i> , 2014, 4, 403-410.	2.7	34
63	Astrocyte loss and astrogliosis in neuroinflammatory disorders. <i>Neuroscience Letters</i> , 2014, 565, 39-41.	2.1	65
64	The <sc>S</sc>ymbol <sc>D</sc>igit <sc>M</sc>odalities <sc>T</sc>est as sentinel test for cognitive impairment in multiple sclerosis. <i>European Journal of Neurology</i> , 2014, 21, 1219.	3.3	133
65	Intravenous thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke in a patient treated with rivaroxaban. <i>Clinical Neurology and Neurosurgery</i> , 2014, 122, 133-134.	1.4	10
66	Headache associated with cough: a review. <i>Journal of Headache and Pain</i> , 2013, 14, 42.	6.0	44
67	Detection of Cognitive Impairment in MS Based on an EEG P300 Paradigm. , 2013, , .		1
68	The sNIHSS-4 predicts outcome in right and left anterior circulation strokes. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 729-731.	1.4	5
69	Self-reported health promotion and disability progression in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2013, 325, 120-126.	0.6	16
70	Neuroprotective efficacy of subcutaneous insulin-like growth factor-I administration in normotensive and hypertensive rats with an ischemic stroke. <i>Neuroscience</i> , 2013, 250, 253-262.	2.3	29
71	Female Gender and Reproductive Factors Affecting Risk, Relapses and Progression in Multiple Sclerosis. <i>Gynecologic and Obstetric Investigation</i> , 2013, 75, 73-84.	1.6	34
72	Rapid Blood-Pressure Lowering in Patients with Acute Intracerebral Hemorrhage. <i>New England Journal of Medicine</i> , 2013, 368, 2355-2365.	27.0	1,269

#	ARTICLE	IF	CITATIONS
73	Performance on Paced Auditory Serial Addition Test and cerebral blood flow in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2013, 128, n/a-n/a.	2.1	13
74	Immune Players in the CNS: The Astrocyte. <i>Journal of NeuroImmune Pharmacology</i> , 2013, 8, 824-839.	4.1	165
75	Cerebral hypoperfusion in multiple sclerosis is reversible and mediated by endothelin-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 5654-5658.	7.1	101
76	Cerebral white matter blood flow and energy metabolism in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1282-1289.	3.0	37
77	Cerebral blood flow velocity changes during upright positioning in bed after acute stroke: an observational study. <i>BMJ Open</i> , 2013, 3, e002960.	1.9	28
78	Unassisted Assessment of Stroke Severity Using Telemedicine. <i>Stroke</i> , 2013, 44, 1249-1255.	2.0	24
79	Prehospital Unassisted Assessment of Stroke Severity Using Telemedicine. <i>Stroke</i> , 2013, 44, 2907-2909.	2.0	60
80	The Effect of Fluoxetine on Progression in Progressive Multiple Sclerosis: A Double-Blind, Randomized, Placebo-Controlled Trial. <i>ISRN Neurology</i> , 2013, 2013, 1-6.	1.5	22
81	Successful Repetitive Intravenous Thrombolysis in a Patient With Recurrent Brainstem Infarctions Due to Megadolichobasilar Ectasia. <i>JAMA Neurology</i> , 2013, 70, 520.	9.0	6
82	Thrombolytic therapy for ischaemic stroke in patients using warfarin: a systematic review and meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 537-540.	1.9	25
83	Exaggerated Postural Blood Pressure Rise Is Related to a Favorable Outcome in Patients With Acute Ischemic Stroke. <i>Stroke</i> , 2012, 43, 92-96.	2.0	16
84	Astrocyte Signaling and Multiple Sclerosis. <i>Current Signal Transduction Therapy</i> , 2012, 7, 14-19.	0.5	0
85	Sunlight exposure and sun sensitivity associated with disability progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 451-459.	3.0	21
86	Variations of Blood Pressure in Stroke Unit Patients May Result from Alternating Body Positions. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2012, 21, 459-466.	1.6	2
87	Associations of alcohol consumption with clinical and MRI measures in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 657-660.	2.8	6
88	Spontaneously hypertensive rats display reduced microglial activation in response to ischemic stroke and lipopolysaccharide. <i>Journal of Neuroinflammation</i> , 2012, 9, 114.	7.2	20
89	Lack of association between serum uric acid levels and outcome in acute ischemic stroke. <i>Journal of the Neurological Sciences</i> , 2012, 319, 51-55.	0.6	32
90	White-Matter Astrocytes, Axonal Energy Metabolism, and Axonal Degeneration in Multiple Sclerosis. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 413-424.	4.3	96

#	ARTICLE	IF	CITATIONS
91	Prediction of hospitalization duration for acute stroke in Belgium. <i>Acta Neurologica Belgica</i> , 2012, 112, 19-25.	1.1	5
92	Menarche, oral contraceptives, pregnancy and progression of disability in relapsing onset and progressive onset multiple sclerosis. <i>Journal of Neurology</i> , 2012, 259, 855-861.	3.6	87
93	Pre-stroke use of beta-blockers does not affect ischaemic stroke severity and outcome. <i>European Journal of Neurology</i> , 2012, 19, 234-240.	3.3	25
94	Intra-arterial blood pressure reading in intensive care unit patients in the lateral position. <i>Journal of Clinical Nursing</i> , 2012, 21, 1825-1830.	3.0	5
95	Acute Stroke Management in Patients Taking Dabigatran. <i>CNS Neuroscience and Therapeutics</i> , 2012, 18, 616-622.	3.9	7
96	Alcohol, coffee, fish, smoking and disease progression in multiple sclerosis. <i>European Journal of Neurology</i> , 2012, 19, 616-624.	3.3	91
97	Interleukin-6, a mental cytokine. <i>Brain Research Reviews</i> , 2011, 67, 157-183.	9.0	305
98	A novel mutation in the SCN4A responsible for cold-induced myotonia with normal electromyography findings on room temperature. <i>Journal of the Neurological Sciences</i> , 2011, 308, 162-164.	0.6	1
99	Late onset painful cold-aggravated myotonia: Three families with SCN4A L1436P mutation. <i>Neuromuscular Disorders</i> , 2011, 21, 590-593.	0.6	12
100	Pharmacologic treatment of depression in multiple sclerosis. <i>The Cochrane Library</i> , 2011, , CD007295.	2.8	53
101	Prior Anticoagulant Therapy, Subtherapeutic International Normalized Ratio and Thrombolytic Therapy in Acute Ischemic Stroke. <i>International Journal of Stroke</i> , 2011, 6, 568-569.	5.9	5
102	Vascular aspects of multiple sclerosis. <i>Lancet Neurology</i> , The, 2011, 10, 657-666.	10.2	195
103	Insulin-Like Growth Factor I Serum Levels Influence Ischemic Stroke Outcome. <i>Stroke</i> , 2011, 42, 2180-2185.	2.0	67
104	Design of a Randomised Controlled Trial (RCT) on the effectiveness of a Dutch patient advocacy case management intervention among severely disabled Multiple Sclerosis patients. <i>BMC Health Services Research</i> , 2010, 10, 142.	2.2	19
105	tPA treatment for acute ischaemic stroke in patients with leukoaraiosis. <i>European Journal of Neurology</i> , 2010, 17, 866-870.	3.3	39
106	T2 lesions and rate of progression of disability in multiple sclerosis. <i>European Journal of Neurology</i> , 2010, 17, 1471-1475.	3.3	26
107	Insulin-like growth factor binding protein-1 activates integrin-mediated intracellular signaling and migration in oligodendrocytes. <i>Journal of Neurochemistry</i> , 2010, 113, 1319-1330.	3.9	22
108	Statin Use and Functional Outcome after Tissue Plasminogen Activator Treatment in Acute Ischaemic Stroke. <i>Cerebrovascular Diseases</i> , 2010, 29, 263-267.	1.7	38

#	ARTICLE	IF	CITATIONS
109	Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in a Stroke Patient Treated with Dabigatran. <i>Cerebrovascular Diseases</i> , 2010, 30, 533-534.	1.7	71
110	Cerebral Autoregulation in Stroke. <i>Stroke</i> , 2010, 41, 2697-2704.	2.0	341
111	Effect of selective serotonin re-uptake inhibitors (SSRIs) on functional outcome in patients with acute ischemic stroke treated with tPA. <i>Journal of the Neurological Sciences</i> , 2010, 293, 65-67.	0.6	8
112	Astrocytes as potential targets to suppress inflammatory demyelinating lesions in multiple sclerosis. <i>Neurochemistry International</i> , 2010, 57, 446-450.	3.8	45
113	Progesterone and dexamethasone differentially regulate the IGF-system in glial cells. <i>Neuroscience Letters</i> , 2010, 468, 178-182.	2.1	43
114	Delayed akinetic catatonic mutism following methadone overdose. <i>NeuroToxicology</i> , 2010, 31, 762-764.	3.0	8
115	Astrocytic β^2 -adrenergic receptors: From physiology to pathology. <i>Progress in Neurobiology</i> , 2010, 91, 189-199.	5.7	54
116	Modifiable factors influencing relapses and disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 773-785.	3.0	69
117	Reduced Creatine Kinase B Activity in Multiple Sclerosis Normal Appearing White Matter. <i>PLoS ONE</i> , 2010, 5, e10811.	2.5	47
118	Risk factors for cerebral venous thrombosis and deep venous thrombosis in patients aged between 15 and 50 years. <i>Thrombosis and Haemostasis</i> , 2009, 102, 620-622.	3.4	18
119	Insulin-Like Growth Factor I. <i>Stroke</i> , 2009, 40, e83-8.	2.0	83
120	Parity and secondary progression in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 676-678.	1.9	63
121	Perfusion computed tomography in the acute phase of mild head injury: Regional dysfunction and prognostic value. <i>Annals of Neurology</i> , 2009, 66, 809-816.	5.3	68
122	Cryptococcal cerebellitis after chemotherapy and autologous stem cell re-infusion in a patient with multiple myeloma. <i>Journal of Neurology</i> , 2009, 256, 145-146.	3.6	11
123	JAK2-V617F mutation in cerebral venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1039-1040.	3.8	6
124	Fatigue, depression and disability accumulation in multiple sclerosis: a cross-sectional study. <i>European Journal of Neurology</i> , 2009, 16, 348-352.	3.3	33
125	Does smoking influence outcome after intravenous thrombolysis for acute ischaemic stroke?. <i>European Journal of Neurology</i> , 2009, 16, 819-822.	3.3	22
126	Thromboelastography in patients with cerebral venous thrombosis. <i>Thrombosis Research</i> , 2009, 124, 185-188.	1.7	22

#	ARTICLE	IF	CITATIONS
127	Long-Term Sequelae after Cerebral Venous Thrombosis in Functionally Independent Patients. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2009, 18, 198-202.	1.6	51
128	Development and validation of a predictive outcome score of cerebral venous thrombosis. <i>Journal of the Neurological Sciences</i> , 2009, 276, 66-68.	0.6	25
129	Hyperdense middle cerebral artery sign and outcome after intravenous thrombolysis for acute ischemic stroke. <i>Journal of the Neurological Sciences</i> , 2009, 285, 114-117.	0.6	29
130	Dietary patterns in clinical subtypes of multiple sclerosis: an exploratory study. <i>Nutrition Journal</i> , 2009, 8, 36.	3.4	36
131	Treatment of seizures in multiple sclerosis. <i>The Cochrane Library</i> , 2009, , CD007150.	2.8	5
132	Adding a subjective dimension to an ICF-based disability measure for people with multiple sclerosis: development and use of a measure for perception of disabilities. <i>Disability and Rehabilitation</i> , 2009, 31, 1008-1017.	1.8	19
133	Thrombolysis for Acute Ischemic Stroke. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 1285-1290.	2.1	10
134	Insulin-like Growth Factor System Regulates Oligodendroglial Cell Behavior: Therapeutic Potential in CNS. <i>Journal of Molecular Neuroscience</i> , 2008, 35, 81-90.	2.3	71
135	An often unrecognized cause of thunderclap headache: reversible cerebral vasoconstriction syndrome. <i>Journal of Headache and Pain</i> , 2008, 9, 389-391.	6.0	36
136	Lipid profile, statin use, and outcome after intravenous thrombolysis for acute ischaemic stroke. <i>Journal of Neurology</i> , 2008, 255, 875-880.	3.6	58
137	Interferon- β treatment and the natural history of relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , 2008, 63, 125-126.	5.3	6
138	Reproducibility over a 1-month period of 1H-MR spectroscopic imaging NAA/Cr ratios in clinically stable multiple sclerosis patients. <i>European Radiology</i> , 2008, 18, 1736-1740.	4.5	11
139	Hypoperfusion of the Cerebral White Matter in Multiple Sclerosis: Possible Mechanisms and Pathophysiological Significance. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2008, 28, 1645-1651.	4.3	101
140	Therapeutic Potential of Fluoxetine in Neurological Disorders. <i>CNS Neuroscience and Therapeutics</i> , 2008, 14, 153-164.	3.9	89
141	Seizures in multiple sclerosis. <i>Epilepsia</i> , 2008, 49, 948-953.	5.1	104
142	CSF oligoclonal bands and progression of disability in multiple sclerosis. <i>European Journal of Neurology</i> , 2008, 15, e24-e24.	3.3	0
143	Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PROFESS) trial: a double-blind, active and placebo-controlled study. <i>Lancet Neurology</i> . The. 2008. 7. 875-884.	10.2	310
144	Impact of fluoxetine on the human brain in multiple sclerosis as quantified by proton magnetic resonance spectroscopy and diffusion tensor imaging. <i>Psychiatry Research - Neuroimaging</i> , 2008, 164, 274-282.	1.8	46

#	ARTICLE	IF	CITATIONS
145	Progression in familial and nonfamilial MS. <i>Multiple Sclerosis Journal</i> , 2008, 14, 300-306.	3.0	12
146	Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke. <i>New England Journal of Medicine</i> , 2008, 359, 1238-1251.	27.0	882
147	The Syndrome of Headache with Neurologic Deficits and Cerebrospinal Fluid Lymphocytosis Mimicking Acute Ischemic Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2008, 17, 246-247.	1.6	5
148	The Incidence of Stroke Mimics Among Stroke Department Admissions in Relation to Age Group. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2008, 17, 418-422.	1.6	56
149	IGF binding protein alterations on periplaque oligodendrocytes in multiple sclerosis: Implications for remyelination. <i>Neurochemistry International</i> , 2008, 52, 1431-1435.	3.8	23
150	Trismus as manifestation of bilateral internal capsule genu infarction. <i>Clinical Neurology and Neurosurgery</i> , 2008, 110, 305-306.	1.4	3
151	Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders. <i>Journal of the Neurological Sciences</i> , 2008, 267, 3-16.	0.6	205
152	Stability and relative validity of the Multiple Sclerosis Impact Profile (MSIP). <i>Disability and Rehabilitation</i> , 2008, 30, 1027-1038.	1.8	24
153	The Multiple Sclerosis Impact Profile (MSIP). Development and testing psychometric properties of an ICF-based health measure. <i>Disability and Rehabilitation</i> , 2008, 30, 261-274.	1.8	39
154	The impact of disabilities on quality of life in people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 972-980.	3.0	79
155	Factors associated with the risk of secondary progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 799-803.	3.0	30
156	Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 1027-1031.	1.9	86
157	Timing of birth and disease progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 793-798.	3.0	14
158	P300 analysis techniques in cognitive impairment after brain injury: Comparison with neuropsychological and imaging data. <i>Brain Injury</i> , 2008, 22, 870-881.	1.2	16
159	Peripheral blood leukocyte NO production and oxidative stress in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 159-165.	3.0	20
160	Fatigue, depression and progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 815-822.	3.0	47
161	Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2008, 359, 1225-1237.	27.0	703
162	Utility of the stroke-thrombolytic predictive instrument. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 1079-1081.	1.9	14

#	ARTICLE	IF	CITATIONS
163	Safety of Antiplatelet Therapy Prior to Intravenous Thrombolysis in Acute Ischemic Stroke. Archives of Neurology, 2008, 65, 607-11.	4.5	67
164	IGF-1 regulates cAMP levels in astrocytes through a β_2 -adrenergic receptor-dependant mechanism. International Journal of Medical Sciences, 2008, 5, 240-243.	2.5	19
165	Targeting Insulin-Like Growth Factor-1 Signaling into the Central Nervous System for Promoting Myelin Repair. Drug Target Insights, 2008, 3, DTI.S362.	1.4	1
166	Routine thrombolysis with intravenous tissue plasminogen activator in acute ischaemic stroke patients aged 80 years or older: a single centre experience. Age and Ageing, 2007, 36, 577-579.	1.6	26
167	Moderate hyperglycaemia is associated with favourable outcome in acute lacunar stroke. Brain, 2007, 130, 1626-1630.	7.6	100
168	Intravenous Alteplase for Stroke. Stroke, 2007, 38, 2612-2618.	2.0	163
169	Reply: Hyperglycaemia and the outcome of stroke. Brain, 2007, 130, e86-e86.	7.6	0
170	Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology, 2007, 68, 1163-1164.	1.1	94
171	The Insulin-like Growth Factor System in Multiple Sclerosis. International Review of Neurobiology, 2007, 79, 203-226.	2.0	48
172	Insulin-like growth factor binding protein-2 as a regulator of IGF actions in CNS: Implications in multiple sclerosis. Cytokine and Growth Factor Reviews, 2007, 18, 267-278.	7.2	47
173	Cigarette smoking and progression in multiple sclerosis. Neurology, 2007, 69, 1515-1520.	1.1	81
174	Structural and functional neuroimaging in mild-to-moderate head injury. Lancet Neurology, The, 2007, 6, 699-710.	10.2	84
175	Plasma S100 β and NSE levels and progression in multiple sclerosis. Journal of the Neurological Sciences, 2007, 252, 154-158.	0.6	20
176	Safety of routine IV thrombolysis between 3 and 4.5h after ischemic stroke. Journal of the Neurological Sciences, 2007, 254, 28-32.	0.6	29
177	Progression in multiple sclerosis: Further evidence of an age dependent process. Journal of the Neurological Sciences, 2007, 255, 35-41.	0.6	83
178	Involvement of morbilliviruses in the pathogenesis of demyelinating disease. Reviews in Medical Virology, 2007, 17, 223-244.	8.3	32
179	Enhanced proliferation of astrocytes from β_2 -adrenergic receptor knockout mice is influenced by the IGF system. Journal of Neurochemistry, 2007, 100, 070209222715079-???	3.9	7
180	Plasma lipid peroxidation and progression of disability in multiple sclerosis. European Journal of Neurology, 2007, 14, 529-533.	3.3	59

#	ARTICLE	IF	CITATIONS
181	Predictive value of clinical characteristics for 'benign' multiple sclerosis. <i>European Journal of Neurology</i> , 2007, 14, 885-889.	3.3	39
182	Pitfalls in the diagnosis of reversible cerebral vasoconstriction syndrome and primary angiitis of the central nervous system. <i>European Journal of Neurology</i> , 2007, 14, 1085-1087.	3.3	33
183	Cerebrospinal fluid oligoclonal bands and progression of disability in multiple sclerosis. <i>European Journal of Neurology</i> , 2007, 14, 797-800.	3.3	40
184	Relationship between the extent of T2 lesions and the onset of secondary progression in multiple sclerosis. <i>European Journal of Neurology</i> , 2007, 14, 1210-1215.	3.3	9
185	Janus faces of microglia in multiple sclerosis. <i>Brain Research Reviews</i> , 2007, 54, 274-285.	9.0	43
186	Tremor in multiple sclerosis. <i>Journal of Neurology</i> , 2007, 254, 133-145.	3.6	180
187	Measuring disability in stroke: relationship between the modified Rankin scale and the Barthel index. <i>Journal of Neurology</i> , 2007, 254, 1113-1117.	3.6	75
188	Surgical resection in metastatic spinal cord compression. <i>Lancet, The</i> , 2006, 367, 109.	13.7	6
189	Simvastatin inhibits interferon-gamma-induced MHC class II up-regulation in cultured astrocytes. <i>Journal of Neuroinflammation</i> , 2006, 3, 16.	7.2	21
190	Erythrocyte membrane fatty acids in benign and progressive forms of multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2006, 244, 123-126.	0.6	17
191	Fluoxetine increases cerebral white matter NAA/Cr ratio in patients with multiple sclerosis. <i>Neuroscience Letters</i> , 2006, 402, 22-24.	2.1	51
192	Acute Posterior Multifocal Placoid Pigment Epitheliopathy With Cerebral Vasculitis: A Multisystem Granulomatous Disease. <i>JAMA Ophthalmology</i> , 2006, 124, 910.	2.4	45
193	Irreversible Neurological Worsening Following High-Dose Corticosteroids in Advanced Progressive Multiple Sclerosis. <i>Clinical Neuropharmacology</i> , 2006, 29, 18-19.	0.7	4
194	Insulin-like growth factor binding proteins: regulation in chronic active plaques in multiple sclerosis and functional analysis of glial cells. <i>European Journal of Neuroscience</i> , 2006, 24, 1645-1652.	2.6	19
195	Benign course in multiple sclerosis: a review. <i>Acta Neurologica Scandinavica</i> , 2006, 113, 359-369.	2.1	106
196	Relationships between brain water content and diffusion tensor imaging parameters (apparent) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 14 898-904.	4.5	15
197	¹ H MR spectroscopy of the brain in multiple sclerosis subtypes with analysis of the metabolite concentrations in gray and white matter: initial findings. <i>European Radiology</i> , 2006, 16, 489-495.	4.5	54
198	Oxidative stress in serum and peripheral blood leukocytes in patients with different disease courses of multiple sclerosis. <i>Journal of Neurology</i> , 2006, 253, 483-487.	3.6	74

#	ARTICLE	IF	CITATIONS
199	5HT4 agonists inhibit interferon- β -induced MHC class II and B7 costimulatory molecules expression on cultured astrocytes. <i>Journal of Neuroimmunology</i> , 2006, 179, 191-195.	2.3	29
200	Uric acid in multiple sclerosis. <i>Neurological Research</i> , 2006, 28, 316-319.	1.3	38
201	Intravenous Tissue Plasminogen Activator in Patients With Stroke Increases the Bioavailability of Insulin-Like Growth Factor-1. <i>Stroke</i> , 2006, 37, 2368-2371.	2.0	12
202	Plasma homocysteine levels in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 189-192.	1.9	89
203	Optimizing Cutoff Scores for the Barthel Index and the Modified Rankin Scale for Defining Outcome in Acute Stroke Trials. <i>Stroke</i> , 2005, 36, 1984-1987.	2.0	243
204	Characterizing the Mechanisms of Progression in Multiple Sclerosis. <i>Archives of Neurology</i> , 2005, 62, 1345.	4.5	105
205	Visual stimulation, 1H MR spectroscopy and fMRI of the human visual pathways. <i>European Radiology</i> , 2005, 15, 47-52.	4.5	27
206	1H Magnetic resonance spectroscopy of the internal capsule in human brain: a feasibility study to detect lactate following contralateral motor activity. <i>European Radiology</i> , 2005, 15, 1349-1352.	4.5	5
207	Analysis of the human brain in primary progressive multiple sclerosis with mapping of the spatial distributions using 1H MR spectroscopy and diffusion tensor imaging. <i>European Radiology</i> , 2005, 15, 1686-1693.	4.5	28
208	Serum uric acid, dehydroepiandrosterone sulphate, and apolipoprotein E genotype in benign vs. progressive multiple sclerosis. <i>European Journal of Neurology</i> , 2005, 12, 514-518.	3.3	27
209	Cluster-Like Headache Aura Status. <i>Headache</i> , 2005, 45, 80-81.	3.9	6
210	Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis. <i>Acta Neurologica Scandinavica</i> , 2005, 112, 1-5.	2.1	88
211	A fatal demyelinating illness in a young woman 10 weeks post partum. <i>Lancet Neurology</i> , The, 2005, 4, 129-134.	10.2	10
212	Pipecolic acid: A diagnostic marker in pyridoxine-dependent epilepsy. <i>Annals of Neurology</i> , 2005, 58, 653-653.	5.3	13
213	Autologous mesenchymal stem cell transplantation in stroke patients. <i>Annals of Neurology</i> , 2005, 58, 653-654.	5.3	31
214	Serum levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in relapsing and primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005, 11, 13-15.	3.0	23
215	The AMPA Antagonist ZK 200775 in Patients with Acute Ischaemic Stroke: A Double-Blind, Multicentre, Placebo-Controlled Safety and Tolerability Study. <i>Cerebrovascular Diseases</i> , 2005, 20, 304-309.	1.7	46
216	Insulin-Like Growth Factor System in Amyotrophic Lateral Sclerosis. , 2005, 9, 160-169.		23

#	ARTICLE	IF	CITATIONS
217	P300 after head injury: Pseudodelay caused by reduced P3A amplitude. <i>Clinical Neurophysiology</i> , 2005, 116, 2606-2612.	1.5	11
218	A randomized crossover study of bee sting therapy for multiple sclerosis. <i>Neurology</i> , 2005, 65, 1764-1768.	1.1	54
219	Serum uric acid levels and leukocyte nitric oxide production in multiple sclerosis patients outside relapses. <i>Journal of the Neurological Sciences</i> , 2005, 231, 41-44.	0.6	26
220	Neuroprotection in acute ischemic stroke. <i>Acta Neurologica Belgica</i> , 2005, 105, 144-8.	1.1	14
221	Acetylsalicylic Acid and Acetaminophen to Combat Elevated Body Temperature in Acute Ischemic Stroke. <i>Cerebrovascular Diseases</i> , 2004, 17, 118-122.	1.7	30
222	Inheritance mode of multiple sclerosis: the effect of HLA class II alleles is stronger than additive. <i>Human Genetics</i> , 2004, 115, 280-284.	3.8	4
223	Enhanced production and proteolytic degradation of insulin-like growth factor binding protein-2 in proliferating rat astrocytes. <i>Journal of Neuroscience Research</i> , 2004, 77, 354-362.	2.9	16
224	Î2-Adrenoceptor involvement in inflammatory demyelination and axonal degeneration in multiple sclerosis. <i>Trends in Pharmacological Sciences</i> , 2004, 25, 67-71.	8.7	40
225	Response to Cosentino et al.: Î2-Adrenoceptors in multiple sclerosis. <i>Trends in Pharmacological Sciences</i> , 2004, 25, 351-352.	8.7	2
226	Insulin-like growth factor binding protein-4 interacts with centrosomes and microtubules in primary astrocytes. <i>Neuroscience</i> , 2004, 125, 381-390.	2.3	11
227	Involvement of insulin-like growth factor binding protein-2 in activated microglia as assessed in post mortem human brain. <i>Neuroscience Letters</i> , 2004, 362, 14-16.	2.1	29
228	N-acetylaspartate: Serum marker of reperfusion in ischemic stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2004, 13, 254-258.	1.6	6
229	Astrocytic Î2-adrenergic receptors and multiple sclerosis. <i>Neurobiology of Disease</i> , 2004, 15, 331-339.	4.4	57
230	Reply to the Letter by van Breda et al.: Reduction of Body Temperature with Paracetamol in Patients with Acute Stroke: Randomized Clinical Trials Are Needed. <i>Cerebrovascular Diseases</i> , 2004, 18, 351-351.	1.7	0
231	Search for morbillivirus proteins in multiple sclerosis brain tissue. <i>NeuroReport</i> , 2004, 15, 27-32.	1.2	14
232	Insulin-like growth factor binding protein-1-6 expression in activated microglia. <i>NeuroReport</i> , 2004, 15, 1033-1037.	1.2	16
233	Peripheral blood leukocyte NO production in MS patients with a benign vs progressive course. <i>Neurology</i> , 2004, 62, 239-242.	1.1	11
234	Involvement of insulin-like growth factor binding protein-2 in activated microglia as assessed in post mortem human brain. <i>Neuroscience Letters</i> , 2004, 362, 14-16.	2.1	2

#	ARTICLE	IF	CITATIONS
235	Reactive astrocytes in chronic active lesions of multiple sclerosis express co-stimulatory molecules B7-1 and B7-2. <i>Journal of Neuroimmunology</i> , 2003, 135, 166-171.	2.3	78
236	Insulin-like growth factor-binding protein 6 inhibits survival and differentiation of rat oligodendrocyte precursor cells. <i>Glia</i> , 2003, 44, 91-101.	4.9	21
237	Free insulin-like growth factor (IGF)-I and IGF binding proteins 2, 5, and 6 in spinal motor neurons in amyotrophic lateral sclerosis. <i>Lancet, The</i> , 2003, 361, 1007-1011.	13.7	85
238	Low leucocyte myeloperoxidase activity in patients with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 953-955.	1.9	16
239	Are Astrocytes Central Players in the Pathophysiology of Multiple Sclerosis?. <i>Archives of Neurology</i> , 2003, 60, 132.	4.5	80
240	Admitting Acute Ischemic Stroke Patients to a Stroke Care Monitoring Unit Versus a Conventional Stroke Unit. <i>Stroke</i> , 2003, 34, 101-104.	2.0	165
241	P300 Component Identification Using Source Analysis Techniques: Reduced Latency Variability. <i>Journal of Clinical Neurophysiology</i> , 2003, 20, 26-34.	1.7	11
242	The Premenstrual Period and Exacerbations in Multiple Sclerosis. <i>European Neurology</i> , 2002, 48, 204-206.	1.4	52
243	AMPA Antagonist ZK200775 in Patients With Acute Ischemic Stroke. <i>Stroke</i> , 2002, 33, 2813-2818.	2.0	63
244	Aminergic receptors in astroglial plaques from patients with multiple sclerosis. <i>Neuroscience Letters</i> , 2002, 331, 87-90.	2.1	12
245	Insulin-like growth factor binding proteins-1 and -2 differentially inhibit rat oligodendrocyte precursor cell survival and differentiation in vitro. <i>Journal of Neuroscience Research</i> , 2002, 69, 207-216.	2.9	29
246	Insulin-like growth factor (IGF)-I binding to a cell membrane associated IGF binding protein-3 acid-labile subunit complex in human anterior pituitary gland. <i>Journal of Neurochemistry</i> , 2002, 82, 430-438.	3.9	3
247	Disappearance of β_2 -adrenergic receptors on astrocytes in canine distemper encephalitis: possible implications for the pathogenesis of multiple sclerosis. <i>NeuroReport</i> , 2001, 12, 191-194.	1.2	19
248	Early prediction of a benign course of multiple sclerosis on clinical grounds: a systematic review. <i>Multiple Sclerosis Journal</i> , 2001, 7, 345-347.	3.0	69
249	Mapping of a susceptibility gene for multiple sclerosis to the 51 kb interval between G511525 and D6S1666 using a new method of haplotype sharing analysis. <i>Neurogenetics</i> , 2001, 3, 221-230.	1.4	31
250	Neurosexology. Guidelines for Neurologists. European Federation of Neurological Societies Task Force on Neurosexology*. <i>European Journal of Neurology</i> , 2001, 8, 2-24.	3.3	34
251	Cooling garment treatment in MS: Clinical improvement and decrease in leukocyte NO production. <i>Neurology</i> , 2001, 57, 892-894.	1.1	80
252	Early prediction of a benign course of multiple sclerosis on clinical grounds: a systematic review. <i>Multiple Sclerosis Journal</i> , 2001, 7, 345-347.	3.0	11

#	ARTICLE	IF	CITATIONS
253	Drug points: Worsening of symptoms of multiple sclerosis associated with carbamazepine. <i>BMJ: British Medical Journal</i> , 2000, 320, 1113-1113.	2.3	57
254	Astrocytes in chronic active multiple sclerosis plaques express MHC class II molecules. <i>NeuroReport</i> , 2000, 11, 89-91.	1.2	71
255	Insulin-like growth factor II receptors in human brain and their absence in astroglitic plaques in multiple sclerosis. <i>Brain Research</i> , 2000, 863, 282-288.	2.2	23
256	Reply. <i>Trends in Neurosciences</i> , 2000, 23, 246.	8.6	0
257	[3H]dihydroalprenolol binding to beta adrenergic receptors in multiple sclerosis brain. <i>Neuroscience Letters</i> , 2000, 289, 75-77.	2.1	59
258	Continuous pulse oximetry in acute hemiparetic stroke. <i>Journal of the Neurological Sciences</i> , 2000, 179, 65-69.	0.6	48
259	Comparison of serum S-100 protein levels following stroke and traumatic brain injury. <i>Journal of the Neurological Sciences</i> , 2000, 181, 104-110.	0.6	94
260	Predicting outcome from coma: man-in-the-barrel syndrome as potential pitfall. <i>Clinical Neurology and Neurosurgery</i> , 2000, 102, 23-25.	1.4	11
261	Use of the Barthel Index and Modified Rankin Scale in Acute Stroke Trials. <i>Stroke</i> , 1999, 30, 1538-1541.	2.0	943
262	Treatment of acute relapses in multiple sclerosis at home with oral dexamethasone: a pilot study. <i>Journal of Clinical Neuroscience</i> , 1999, 6, 382-384.	1.5	10
263	Peptidylarginine deiminase activity in postmortem white matter of patients with multiple sclerosis. <i>Neuroscience Letters</i> , 1999, 260, 74-76.	2.1	22
264	Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing?. <i>Trends in Neurosciences</i> , 1999, 22, 535-540.	8.6	344
265	Low-dose versus high-dose acetylsalicylic acid in carotid endarterectomy. <i>Lancet, The</i> , 1999, 354, 1034.	13.7	1
266	From stroke unit care to stroke care unit. <i>Journal of the Neurological Sciences</i> , 1999, 162, 1-5.	0.6	14
267	Safety of tetanus vaccination in relapsing-remitting multiple sclerosis. <i>Infection</i> , 1998, 26, 319-319.	4.7	7
268	Antipyretics in acute ischaemic stroke. <i>Lancet, The</i> , 1998, 352, 6-7.	13.7	36
269	Placebo-controlled multicentre randomised trial of interferon β -1b in treatment of secondary progressive multiple sclerosis. <i>Lancet, The</i> , 1998, 352, 1491-1497.	13.7	961
270	Increased serum neuron specific enolase concentrations in patients with hyperglycemic cortical ischemic stroke. <i>Neuroscience Letters</i> , 1998, 253, 71-73.	2.1	24

#	ARTICLE	IF	CITATIONS
271	Insulin-like growth factor system in serum and cerebrospinal fluid in patients with multiple sclerosis. <i>Neuroscience Letters</i> , 1998, 257, 168-170.	2.1	21
272	Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 1998, 159, 51-53.	0.6	109
273	Premenstrual exacerbations of multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1998, 65, 279-280.	1.9	18
274	Thrombolytic therapy for acute ischemic stroke. <i>Neurology</i> , 1997, 49, 900-901.	1.1	0
275	Risks of multiple sclerosis in relatives of patients in Flanders, Belgium.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997, 62, 329-333.	1.9	83
276	Early outcome in acute ischemic stroke is not influenced by the prophylactic use of low-dose aspirin. <i>Journal of the Neurological Sciences</i> , 1997, 145, 93-96.	0.6	24
277	Menstrually related worsening of symptoms in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 1997, 149, 95-97.	0.6	91
278	Oral versus intravenous corticosteroids in acute relapses of multiple sclerosis. <i>Lancet, The</i> , 1997, 349, 1696.	13.7	10
279	Safety and pharmacokinetics of the neuroprotective drug lubeluzole in patients with ischemic stroke. <i>Clinical Therapeutics</i> , 1997, 19, 1340-1351.	2.5	9
280	Insulin-like growth factor-I receptors in normal appearing white matter and chronic plaques in multiple sclerosis. <i>Brain Research</i> , 1997, 772, 243-246.	2.2	30
281	Platelet-derived growth factor receptors in the human central nervous system: autoradiographic distribution and receptor densities in multiple sclerosis. <i>Neuroscience Research Communications</i> , 1997, 21, 179-186.	0.2	0
282	Lubeluzole in Acute Ischemic Stroke. <i>Stroke</i> , 1996, 27, 76-81.	2.0	123
283	Dopamine agonists used in the treatment of Parkinson's disease and their selectivity for the D1, D2, and D3 dopamine receptors in human striatum. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1995, 19, 1147-1154.	4.8	35
284	Intravenous Nimodipine West European Stroke Trial (INWEST) of Nimodipine in the Treatment of Acute Ischaemic Stroke. <i>Cerebrovascular Diseases</i> , 1994, 4, 204-210.	1.7	277
285	Neurological Scales in the Assessment of Cerebral Infarction. <i>Cerebrovascular Diseases</i> , 1994, 4, 7-14.	1.7	27
286	Self-Treatment of Acute Migraine with Subcutaneous Sumatriptan Using an Auto-Injector Device: Comparison With Customary Treatment in An Open, Longitudinal Study. <i>Cephalalgia</i> , 1994, 14, 55-63.	3.9	35
287	Insulin-like growth factor-I receptors in human brain and pituitary gland: An autoradiographic study. <i>Synapse</i> , 1994, 17, 196-202.	1.2	56
288	[3H]Clozapine is not a suitable radioligand for the labelling of D4 dopamine receptors in postmortem human brain. <i>Neuroscience Letters</i> , 1994, 175, 17-20.	2.1	19

#	ARTICLE	IF	CITATIONS
289	Autoradiographic distribution of D3-type dopamine receptors in human brain using [3H]7-hydroxy-N,N-di-n-propyl-2-aminotetralin. Brain Research, 1994, 648, 222-228.	2.2	93
290	Hospital referral of stroke patients: a survey of attitudes in general practice, and consideration of entry times for clinical trials. Clinical Neurology and Neurosurgery, 1994, 96, 32-37.	1.4	7
291	Miller Fisher syndrome associated with Mycoplasma pneumoniae infection: report of a case. Clinical Neurology and Neurosurgery, 1994, 96, 96-99.	1.4	17
292	Insulin-like growth factor-I receptor densities in human frontal cortex and white matter during aging, in Alzheimer's disease, and in Huntington's disease. Neuroscience Letters, 1994, 172, 93-96.	2.1	39
293	Imidazoline receptors, non-adrenergic idazoxan binding sites and $\hat{1}\pm 2$ -adrenoceptors in the human central nervous system. Neuroscience, 1994, 59, 589-598.	2.3	148
294	The European Stroke Scale.. Stroke, 1994, 25, 2215-2219.	2.0	170
295	Bromocriptine Therapy in Multiple Sclerosis. Clinical Neuropharmacology, 1994, 17, 473-476.	0.7	39
296	Subtypes and localization of dopamine receptors in human brain. Neurochemistry International, 1993, 22, 83-93.	3.8	36
297	$\hat{1}\pm 2A$ Adrenoceptors and non-adrenergic idazoxan binding sites in calf brain and retina are distinct from those in human brain. Neurochemistry International, 1993, 22, 501-509.	3.8	6
298	What intracranial tissues in humans contain sumatriptan-sensitive serotonin 5-HT1-type receptors?. Neuroscience Letters, 1993, 164, 63-66.	2.1	17
299	Guillainâ€Barrel's syndrome as the presenting manifestation of hepatitis C infection. Neurology, 1993, 43, 2143-2143.	1.1	37
300	Serum concentrations of vitamins A and E and early outcome after ischaemic stroke. Lancet, The, 1992, 339, 1562-1565.	13.7	44
301	Cyclosporin leukoencephalopathy induced by intravenous lipid solution. Lancet, The, 1992, 339, 1114.	13.7	50
302	6.4 Identification of $\hat{2}$ adrenoceptors in the human nucleus olivarius by radioligand binding. Progress in Histochemistry and Cytochemistry, 1992, 26, 259-265.	5.1	0
303	Idiopathic hemiparetic parkinsonism, a syndrome distinct from idiopathic parkinsonism. Lancet, The, 1992, 339, 149-150.	13.7	1
304	Regional Distribution of $\hat{2}A$ -and $\hat{2}B$ -Adrenoceptor Subtypes in Postmortem Human Brain. Journal of Neurochemistry, 1992, 58, 1555-1560.	3.9	80
305	Loss of high-affinity agonist receptor binding in Alzheimer's disease. Annals of Neurology, 1992, 31, 231-231.	5.3	2
306	Meningoencephalitis caused by Rickettsia Conorii. Clinical Neurology and Neurosurgery, 1991, 93, 345-347.	1.4	6

#	ARTICLE	IF	CITATIONS
307	Strokes soon after oral anticoagulant therapy in patients with atrial fibrillation. <i>Lancet, The</i> , 1991, 338, 1158.	13.7	1
308	Sudden hypotonic paraparesis caused by tophaceous gout of the lumbar spine. <i>Clinical Neurology and Neurosurgery</i> , 1991, 93, 233-236.	1.4	21
309	Increase in serum myoglobin, creatine kinase, and free fatty acids, during recovery from a paralytic attack in hypokalemic periodic paralysis. <i>Clinical Neurology and Neurosurgery</i> , 1991, 93, 241-243.	1.4	2
310	Autoradiographic distribution of β_2 adrenoceptors, NAIBS, and 5-HT _{1A} receptors in human brain using [³ H]idazoxan and [³ H]rauwolscine. <i>Brain Research</i> , 1991, 566, 13-20.	2.2	70
311	Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine. <i>Lancet, The</i> , 1991, 338, 1174-1175.	13.7	157
312	Vertebral Artery Occlusion Complicating Perimetry. <i>American Journal of Ophthalmology</i> , 1991, 111, 516-517.	3.3	3
313	Excitotoxic Mechanisms May Be Involved in the Pathophysiology of Tardive Dyskinesia. <i>Clinical Neuropharmacology</i> , 1991, 14, 562-566.	0.7	47
314	D ₁ and D ₂ Dopamine Receptors in Human Substantia Nigra: Localization and the Effect of Aging. <i>Journal of Neurochemistry</i> , 1991, 56, 1130-1133.	3.9	17
315	A Wernicke's encephalopathy-like neurotoxicity induced by erbulozole. <i>Neurology</i> , 1991, 41, 762-763.	1.1	1
316	Age-related changes in the human nigrostriatal dopaminergic system. <i>Annals of Neurology</i> , 1990, 27, 157-161.	5.3	139
317	D ₁ -Dopamine Receptor Abnormality in Frontal Cortex Points to a Functional Alteration of Cortical Cell Membranes in Alzheimer's Disease. <i>Archives of Neurology</i> , 1990, 47, 761-763.	4.5	49
318	Human M ₁ -, M ₂ - and M ₃ -muscarinic cholinergic receptors: Binding characteristics of agonists and antagonists. <i>Journal of the Neurological Sciences</i> , 1990, 97, 67-80.	0.6	32
319	The effect of aging on the D ₁ dopamine receptors in human frontal cortex. <i>Brain Research</i> , 1990, 528, 308-310.	2.2	89
320	Neostriatal dopamine receptors. <i>Trends in Neurosciences</i> , 1990, 13, 324.	8.6	3
321	In Human Brain Two Subtypes of D ₁ Dopamine Receptors Can Be Distinguished on the Basis of Differences in Guanine Nucleotide Effect on Agonist Binding. <i>Journal of Neurochemistry</i> , 1989, 53, 1096-1102.	3.9	28
322	[³ H]GBR 12935 Binding to Dopamine Uptake Sites in the Human Brain. <i>Journal of Neurochemistry</i> , 1989, 53, 1400-1404.	3.9	52
323	Lack of GTP-insensitive D ₂ dopamine receptors in Huntington's disease. <i>Journal of the Neurological Sciences</i> , 1989, 92, 329-335.	0.6	6
324	(\pm)Tetrahydroanisocycline and (\pm)tetrahydropalmatine binding to D ₁ and D ₂ dopaminergic receptors in human putamen. <i>Neurochemistry International</i> , 1989, 15, 321-324.	3.8	5

#	ARTICLE	IF	CITATIONS
325	[3H]Rauwolscine labels $\hat{1}\pm 2$ -adrenoceptors and 5-HT _{1A} receptors in human cerebral cortex. European Journal of Pharmacology, 1989, 159, 307-310.	3.5	38
326	[3H]SCH 23390 labels a novel 5-hydroxytryptamine binding site in human blood platelet membranes. European Journal of Pharmacology, 1989, 162, 437-445.	3.5	21
327	D2 dopamine receptors in the human brain: heterogeneity based on differences in guanine nucleotide effect on agonist binding, and their presence on corticostriatal nerve terminals. Brain Research, 1989, 484, 36-42.	2.2	36
328	Coupling of D1 dopamine receptors to the guanine nucleotide binding protein G _s is deficient in Huntington's disease. Brain Research, 1989, 496, 327-330.	2.2	18
329	Monoaminergic neurotransmitters in Alzheimer's disease. Journal of the Neurological Sciences, 1989, 92, 101-116.	0.6	35
330	High affinity binding of 3H rauwolscine and 3H RX781094 to $\hat{1}\pm 2$ adrenergic receptors and non-stereo selective sites in human and rabbit brain cortex membranes. Biochemical Pharmacology, 1989, 38, 455-463.	4.4	63
331	Evidence for a widespread dopaminergic innervation of the human cerebral neocortex. Neuroscience Letters, 1989, 104, 281-285.	2.1	60
332	D1 dopamine receptors in human putamen, frontal cortex and calf retina: differences in guanine nucleotide regulation of agonist binding and adenylate cyclase stimulation. Brain Research, 1988, 443, 77-84.	2.2	60
333	Quantitation of ultrastructure by light microscopical image analysis. Biology of the Cell, 1988, 63, 27-27a.	2.0	0
334	Autoradiographic localization of D1 and D2 dopamine receptors in the human brain. Neuroscience Letters, 1988, 91, 142-147.	2.1	116
335	Identification of D1-like dopamine receptors on human blood platelets. Life Sciences, 1988, 42, 1797-1806.	4.3	25
336	Subtypes of adrenergic and dopaminergic receptors in bovine cerebral blood vessels. Neuroscience Letters, 1988, 85, 272-276.	2.1	14
337	Letters to the Editor. International Journal of Epidemiology, 1987, 16, 484-485.	1.9	0
338	Flunitrazepam intoxication simulating a structural brainstem lesion.. Journal of Neurology, Neurosurgery and Psychiatry, 1987, 50, 236-237.	1.9	3
339	Hormonal Changes during a Spontaneous Attack of Hypokalemic Periodic Paralysis. European Neurology, 1987, 26, 60-64.	1.4	1
340	Rhabdomyolysis in hypokalaemic periodic paralysis: a clue to the mechanism that terminates the paralytic attack?. Journal of Neurology, 1987, 234, 119-121.	3.6	17
341	Brain stem infarction as a complication of giant-cell arteritis. Clinical Neurology and Neurosurgery, 1986, 88, 127-129.	1.4	5
342	Disappearance of Akathisia Following Electroconvulsive Treatment. Clinical Neuropharmacology, 1986, 9, 563-565.	0.7	2

#	ARTICLE	IF	CITATIONS
343	D2Dopamine Receptors in Calf Globus Pallidus: Agonist High- and Low-Affinity Sites Not Regulated by Guanine Nucleotide. Journal of Neurochemistry, 1985, 45, 977-979.	3.9	22
344	The role of childbirth on the natural history of occult spinal dysraphism.. Journal of Neurology, Neurosurgery and Psychiatry, 1985, 48, 721-722.	1.9	3
345	Enophthalmos as a rare manifestation of metastatic orbital involvement. Postgraduate Medical Journal, 1985, 61, 149-152.	1.8	5
346	COMA as presenting manifestation of Wernicke's encephalopathy. Journal of Emergency Medicine, 1985, 3, 361-363.	0.7	9
347	Regional distribution of the dopamine D2 receptors in the mesotelencephalic dopamine neuron system of human brain. Journal of the Neurological Sciences, 1985, 71, 119-127.	0.6	33
348	Lower motor neuron disease in a patient with hodgkin's disease treated with radiotherapy. Clinical Neurology and Neurosurgery, 1984, 86, 43-46.	1.4	11
349	Osteopathia striata with cranial sclerosis. Clinical Neurology and Neurosurgery, 1983, 85, 41-48.	1.4	21
350	Sudden hearing loss and facial palsy at the contralateral side following acoustic tumour removal.. Journal of Neurology, Neurosurgery and Psychiatry, 1983, 46, 687-687.	1.9	18